fbpx

Daxocox®

Go back

Daxocox®

Species:
Actives:

Pack Size:
Product Code:
Legal Category: 
 

The first and only weekly oral NSAID, for consistent OA pain and inflammation management.

 

Indicated for the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs.

   

For more information on Daxocox®, please visit www.daxocox.co.uk

Further Information

Daxocox®

  • The first and only weekly oral NSAID
  • A novel answer to canine OA and breakthrough pain management
  • Plasma levels remain stable at the required therapeutic level for 7 days1
  • Licensed for all stages of OA
  • Can be given continuously, with no risk of over-accumulation or requirement for mandatory treatment breaks
  • After treatment with Daxocox vets reported that 74% of dogs don’t show clinical signs of OA2
  • Owners reported, after treatment, that 84% of dogs improved their quality of life from ‘poor or fair’ to ‘good, very good or excellent’2

 

1. Internal report: PK_001_2018, pending publication
2. Internal report: DA/197/C, pending publication

 

UK POM-V, 15mg Vm 32742/5001, 30mg Vm 32742/5002, 45mg Vm 32742/5003, 70mg Vm 32742/5004, 100mg Vm 32742/5005.
Further information can be found in the SPC, the datasheet or the pack leaflet.
USE MEDICINES RESPONSIBLY. Daxocox® is a registered trademark of Animalcare Group Plc

 

Description

 

The first and only weekly oral NSAID, for consistent OA pain and inflammation management.

 

Indicated for the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs.

 
 

For more information on Daxocox®, please visit www.daxocox.co.uk